Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Cardiff Oncology, a clinical-stage biotech company focused on PLK1 inhibition for cancer treatment, has entered into definitive agreements for a $10 million registered direct offering of common shares and warrants. The proceeds will be primarily used for working capital and general corporate purposes to support ongoing clinical trials, especially o…
Genius Group Limited (NYSE American: GNS) has set July 31, 2026, as the record date for the second round of its Share Loyalty Bonus Program, with a bonus of $0.10 per qualifying share. This initiative follows a successful first round, encouraging shareholders to maintain their shares in book entry to receive the bonus, which equates to 56% of the c…
UroGen Pharma Ltd. announced the receipt of a U.S. patent allowance for methods treating low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) using its proprietary RTGel technology delivering mitomycin. The patent protection is expected to extend until July 2044, reinforcing the intellectual property foundation for its FDA-a…
The Chefs’ Warehouse, Inc. announced it will release its financial results for the second quarter of 2026 on July 29, 2026, before the market opens. The company will host a conference call the same day to discuss the results. The Chefs’ Warehouse distributes specialty food products primarily in the U.S., Middle East, and Canada, serving chefs and f…
Glass House Brands Inc. announced an update to its at-the-market equity distribution program permitting sales of up to $100 million in shares on both the NYSE and Canadian markets. The funds will be used for cultivation expansion, potential acquisitions, and general corporate purposes. The ATM program is to be used opportunistically as a long-term …
ENvue Medical has appointed Dr. Zeev Rotstein as Chairman of the Board and added Zvi Joseph and Lior Buchman as new directors, bringing extensive expertise in healthcare leadership, AI governance, and capital markets. These strategic board changes support ENvue's momentum in advancing its real-time guided bedside feeding tube placement technology a…
Belite Bio, a clinical-stage biopharmaceutical company targeting degenerative retinal diseases, announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference where it will present its development progress, including successful Phase 3 trial results and ongoing late-stage clinical trials for its lead oral therapy tin…
BlackRock shares climbed sharply in pre-market trading after the asset manager reported second-quarter results that exceeded analyst forecasts across key metrics. Adjusted EPS and revenue both outpaced Street estimates, while assets under management surpassed $15 trillion, supported by substantial net client inflows and strong interest in the firm'…
Oppenheimer downgraded IBM to Perform and removed its $350 price target after IBM pre-announced weaker-than-expected second-quarter 2026 results. The firm said revenue missed across every segment, with total revenue up 1% year-over-year to $17.2 billion. Software growth lagged estimates, infrastructure revenue declined, and consulting was flat, pro…
Warren Buffett told CNBC he personally initiated Berkshire Hathaway's recent investment in Alphabet and remains comfortable operating with new CEO Greg Abel. Buffett highlighted the heavy capital demands of AI competition as a key challenge for Alphabet and peers, and reiterated that Apple remains one of Berkshire's favorite equity holdings.
Aehr Test Systems stock jumped sharply in pre-market trading after the company posted fiscal fourth-quarter results that beat estimates across the board, reported record bookings and backlog, and outlined a fiscal 2027 revenue target that materially exceeds street expectations. Management highlighted a rapid shift in end-market mix away from electr…
Ernexa Therapeutics stock climbed 30% after an independent contract research organization reproduced earlier preclinical findings showing complete tumor clearance and long-term survival in ovarian cancer models when ERNA-101 was given with anti-PD-1 therapy. The validation supports the company's timeline toward an Investigational New Drug submissio…
Canadian stock index futures moved marginally lower ahead of a pivotal Bank of Canada announcement, as traders weigh a rebound in commodities and mining equities against rising energy-driven inflation risks stemming from renewed geopolitical pressure in the Middle East. Market participants are focused on the BoC's updated growth and inflation outlo…
Ernexa Therapeutics announced independent validation of its lead cell therapy candidate ERNA-101 in combination with anti-PD-1 treatment, achieving complete tumor clearance and long-term survival in 67% of treated animals in ovarian cancer models. No complete responses were observed in monotherapy or control groups. This robust third-party study en…
Warren Buffett said he informed Bill Gates that he would stop directing Berkshire Hathaway stock gifts to the Gates Foundation, a decision he described as unsurprising after reviewing materials related to Gates' interactions with Jeffrey Epstein. Instead, Buffett will allocate nearly $6 billion in Berkshire shares to four family foundations adminis…
Uber's core marketplaces - Mobility, Delivery and Freight - are generating durable free cash flow and improving unit economics. At roughly $72 a share, the stock offers a reasonable multiple on strong ROE and free cash flow generation. This trade targets upside back toward the $100 area while protecting downside below the 52-week low with a tight s…
Profound Medical Corp. announced its advanced MRI-guided, AI-powered, robotically-driven TULSA Procedure for incisionless prostate ablation will be featured prominently at the Society of Robotic Surgery Annual Meeting (SRS2026). The company will participate in multiple presentations, including clinical outcomes and safety data, as well as an invest…
Gildan Activewear Inc. announced that it will report its second quarter 2026 financial and operating results on July 30, 2026. The company will issue a press release before US market open followed by a conference call featuring top executives to discuss the results. Gildan is a vertically integrated manufacturer of basic apparel brands and operates…
Stripe and Advent International have reportedly proposed a $53 billion takeover of PayPal at $60.50 per share, a 28% premium to the most recent close. Michael Burry, who holds PayPal as a top deep-value position, publicly rejected the offer as too low, citing his intrinsic value metrics and arguing a realistic winning bid would be closer to $100 pe…
Kratos (KTOS) trades near $51 after a pullback from its 52-week high. The headline price swings mask a healthier setup: strong funded backlog and liquidity, low debt, and a sizable short base that can compress on positive contract flow. This is a mid-term swing trade that buys into defense tailwinds while respecting execution and cash-flow risk.
Morgan Stanley reported an increase in second-quarter profit, driven largely by elevated mergers and acquisitions activity and stronger investment banking fees. A permissive regulatory backdrop and robust equity markets supported dealmaking, producing record first-half M&A totals and boosting underwriting and advisory revenue for the bank.
Centene shares fell about 3.8% in pre-market activity to $66.10 after reaching a 52-week peak of $69.36 in the previous session. The pullback follows investor concern over weaker-than-expected margins reported by Elevance Health and rising medical costs that could pressure insurer profitability. Analyst target adjustments are mixed and the stock fa…
Repligen Corporation, a life sciences company specializing in bioprocessing technologies, announced it will report its second quarter 2026 financial results on July 28, 2026. A conference call and webcast will follow to discuss business updates and financial outcomes for the quarter ending June 30, 2026.
Cellectar Biosciences announced the publication of the Phase 1 study results of iopofosine I 131 combined with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients. The study demonstrated a manageable safety profile with predominantly hematologic toxicities and showed encouraging clinical activity, supporting c…
Acumen Pharmaceuticals presented new preclinical data demonstrating that their Enhanced Brain Delivery™ (EBD™) bispecific antibodies achieved markedly improved brain penetration in non-human primates compared to native antibodies. Notably, candidate ACU401 showed up to 40-fold higher frontal cortex exposure with no hematological safety concerns, su…
